8. Huntington disease Clinical trials / Disease details
Clinical trials : 242 / Drugs : 205 - (DrugBank : 62) / Drug target genes : 85 - Drug target pathways : 159
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05238701 (ClinicalTrials.gov) | February 28, 2022 | 9/1/2022 | A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects | A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 Sustained-release Tablets in Healthy Subjects | Huntington Disease;Tardive Dyskinesia | Drug: LPM3770164 sustained release tablet;Drug: LPM3770164 sustained release tablet simulant | Luye Pharma Group Ltd. | NULL | Not yet recruiting | 18 Years | 45 Years | All | 104 | Phase 1 | China |
| 2 | NCT01795859 (ClinicalTrials.gov) | August 5, 2013 | 20/2/2013 | First Time Use of SD-809 in Huntington Disease | A Randomized Double-Blind, Placebo-Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease | Chorea | Drug: SD-809;Drug: Placebo | Teva Pharmaceutical Industries | NULL | Completed | 18 Years | N/A | All | 90 | Phase 3 | United States;Australia;Canada |
| 3 | NCT00990613 (ClinicalTrials.gov) | October 2009 | 6/10/2009 | A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The Skin | A Phase 1, Fixed Sequence, Cross-Over Study To Investigate The Single Dose Pharmacokinetics Of A Dimebon (Latrepirdine) Transdermal Solution Relative To The Immediate Release Formulation In Older Adults | Alzheimer's Disease;Huntington's Disease | Drug: Dimebon IR;Drug: Dimebon Transdermal | Pfizer | Medivation, Inc. | Completed | 50 Years | 85 Years | Both | 19 | Phase 1 | United States |
| 4 | NCT00988624 (ClinicalTrials.gov) | October 2009 | 1/10/2009 | A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine) | A Phase 1, Randomized, Open-Label, Single Dose Cross-Over Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine) | Alzheimer's Disease;Huntington Disease | Drug: Dimebon IR Tablet;Drug: Dimebon MR1;Drug: Dimebon MR2;Drug: Dimebon MR3;Drug: Dimebon MR4 | Pfizer | Medivation, Inc. | Completed | 18 Years | 55 Years | Both | 20 | Phase 1 | United States |